These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32408515)

  • 1. Advantages of Using Paclitaxel in Combination with Oncolytic Adenovirus Utilizing RNA Destabilization Mechanism.
    Hossain E; Habiba U; Yanagawa-Matsuda A; Alam A; Ahmed I; Alam MT; Yasuda M; Higashino F
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32408515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced oncolytic activity of E4orf6-deficient adenovirus by facilitating nuclear export of HuR.
    Ahmed I; Alam MT; Yanagawa-Matsuda A; Hossain E; Kitamura T; Minowa K; Higashino F
    Biochem Biophys Res Commun; 2020 Aug; 529(2):494-499. PubMed ID: 32703457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditionally Replicative Adenovirus Controlled by the Stabilization System of AU-Rich Elements Containing mRNA.
    Mikawa Y; Towfik Alam M; Hossain E; Yanagawa-Matsuda A; Kitamura T; Yasuda M; Habiba U; Ahmed I; Kitagawa Y; Shindoh M; Higashino F
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32403262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus.
    Kasala D; Lee SH; Hong JW; Choi JW; Nam K; Chung YH; Kim SW; Yun CO
    Biomaterials; 2017 Nov; 145():207-222. PubMed ID: 28869866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic potential of an E4-deficient adenovirus that can recognize the stabilization of AU-rich element containing mRNA in cancer cells.
    Yanagawa-Matsuda A; Mikawa Y; Habiba U; Kitamura T; Yasuda M; Towfik-Alam M; Kitagawa Y; Minowa K; Shindoh M; Higashino F
    Oncol Rep; 2019 Feb; 41(2):954-960. PubMed ID: 30431137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
    Bieler A; Mantwill K; Dravits T; Bernshausen A; Glockzin G; Köhler-Vargas N; Lage H; Gansbacher B; Holm PS
    Hum Gene Ther; 2006 Jan; 17(1):55-70. PubMed ID: 16409125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin Relocalizes RNA Binding Protein HuR and Enhances the Oncolytic Activity of E4orf6 Deleted Adenovirus.
    Habiba U; Hossain E; Yanagawa-Matsuda A; Chowdhury AFMA; Tsuda M; Zaman AU; Tanaka S; Higashino F
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32230919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
    Stoff-Khalili MA; Rivera AA; Nedeljkovic-Kurepa A; DeBenedetti A; Li XL; Odaka Y; Podduturi J; Sibley DA; Siegal GP; Stoff A; Young S; Zhu ZB; Curiel DT; Mathis JM
    Breast Cancer Res Treat; 2008 Mar; 108(1):43-55. PubMed ID: 17508279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.
    Fukuda K; Abei M; Ugai H; Kawashima R; Seo E; Wakayama M; Murata T; Endo S; Hamada H; Hyodo I; Yokoyama KK
    Cancer Gene Ther; 2009 Feb; 16(2):126-36. PubMed ID: 18818710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors.
    van Beusechem VW; Mastenbroek DC; van den Doel PB; Lamfers ML; Grill J; Würdinger T; Haisma HJ; Pinedo HM; Gerritsen WR
    Gene Ther; 2003 Nov; 10(23):1982-91. PubMed ID: 14528322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
    Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
    Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth.
    Yoon AR; Hong J; Yun CO
    Oncotarget; 2015 Oct; 6(33):34875-91. PubMed ID: 26430798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
    Shashkova EV; Spencer JF; Wold WS; Doronin K
    Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region.
    Danielsson A; Dzojic H; Nilsson B; Essand M
    Cancer Gene Ther; 2008 Apr; 15(4):203-13. PubMed ID: 18188185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
    Melquist JJ; Kacka M; Li Y; Malaeb BS; Elmore J; Baseman AG; Hsieh JT; Koeneman KS
    Urol Oncol; 2006; 24(4):362-71. PubMed ID: 16818192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.